Galera Therapeutics (GRTX)
(Delayed Data from OTC)
$0.08 USD
0.00 (0.00%)
Updated Sep 20, 2024 03:47 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
GRTX 0.08 0.00(0.00%)
Will GRTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GRTX
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
GRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
Other News for GRTX
Galera Announces Board Approval of Complete Liquidation and Dissolution
Galera Therapeutics Announces Wind-Up and Special Stockholder Meeting
Galera Therapeutics reports Q2 EPS (7c) vs. (48c) last year
Galera Therapeutics announces board approval of liquidation, dissolution
Galera Therapeutics to reduce workforce to three employees